Fluicell AB (SE:FLUI)
:FLUI
Want to see SE:FLUI full AI Analyst Report?
Top Page
Fluicell AB
(FLUI)
Select Model
Select Model
Rating:61Neutral
Price Target:
kr36.00
▲(260.00% Upside)
Action:Reiterated
Date:05/23/26
The score is driven by strong technical momentum with the stock trading well above key moving averages and positive MACD. This is offset by weak financial performance dominated by persistent losses and ongoing cash burn despite improving revenue and a debt-free balance sheet. Valuation is moderately supportive based on the very low P/E, but the absence of dividend yield tempers that support.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure reduces refinancing risk and interest burden, preserving flexibility to invest in R&D and product commercialization. Over 2-6 months this supports survivability and strategic optionality while management pursues commercial traction and partnerships.
Negative Factors
Persistent negative cash flow
Ongoing negative operating and free cash flow indicate the company cannot self-finance growth yet and will need external funding. This structural cash burn elevates dilution or financing risk over the next several quarters and limits reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure reduces refinancing risk and interest burden, preserving flexibility to invest in R&D and product commercialization. Over 2-6 months this supports survivability and strategic optionality while management pursues commercial traction and partnerships.
Read all positive factors
Fluicell AB (FLUI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr42.17M
Dividend YieldN/A
Average Volume (3M)16.23K
Price to Earnings (P/E)1.2
Beta (1Y)1.12
Revenue Growth573.00%
EPS Growth80.00%
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Fluicell AB Business Overview & Revenue Model
Company Description
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery...
How the Company Makes Money
null...
Fluicell AB Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.87M | 6.00M | 1.86M | 3.34M | 3.25M | 2.60M |
| Gross Profit | 8.22M | -8.69M | 3.76M | 1.74M | 2.59M | 1.89M |
| EBITDA | -2.96M | -8.31M | -14.99M | -25.91M | -20.89M | -21.08M |
| Net Income | -2.35M | -8.33M | -15.51M | -26.55M | -21.49M | -21.72M |
Balance Sheet | ||||||
| Total Assets | 20.77M | 18.48M | 25.51M | 9.34M | 31.77M | 26.98M |
| Cash, Cash Equivalents and Short-Term Investments | 1.30M | 2.26M | 15.92M | 2.76M | 24.46M | 20.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.56M | 7.57M | 6.27M | 8.91M | 8.32M | 7.87M |
| Stockholders Equity | 14.21M | 10.90M | 19.23M | 425.00K | 23.45M | 19.11M |
Cash Flow | ||||||
| Free Cash Flow | -8.47M | 0.00 | -15.67M | -27.23M | -22.18M | -19.41M |
| Operating Cash Flow | -902.00K | -4.95M | -15.67M | -27.23M | -21.04M | -18.64M |
| Investing Cash Flow | -7.48M | -8.67M | -3.49M | 0.00 | -1.14M | -772.00K |
| Financing Cash Flow | -1.00K | 0.00 | 32.32M | 5.53M | 25.94M | 21.31M |
Fluicell AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:FLUI
Fluicell AB
34.50
23.30
208.04%
DE:65G
NextCell Pharma AB
0.09
<0.01
10.00%
DE:COJ0
CombiGene AB
0.16
-0.01
-8.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.